Pharmaceutical Corruption News Articles

Excerpts of key news articles on

Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: Explore our full index to revealing excerpts of key major media news articles on dozens of engaging topics. And read excerpts from 20 of the most revealing news articles ever published.

Too many people are being prescribed antidepressants to deal with stressful life events or social problems, according to a growing chorus of doctors and researchers. More than 14% of Australians are currently taking antidepressants, one of the highest rates in the world. Dr Matt Fisher, who researches wellbeing and the impact of stress, says while he has heard health workers talk about this "as a good thing, because it means more people are getting access to help", he doesn't see it as a success story. Fisher ... is concerned Australia's high use of antidepressants "constitutes a failed attempt to medicate away what are, in fact, social problems". He says while "antidepressants may be of benefit to some people suffering persistent psychosocial distress," they should not be the default, first response. Chronic stress, where people are exposed to an ongoing, recurrent stressor without any easy or accessible way to resolve it – increasing the risk of isolation, exclusion, humiliation and harm – is a significant driver of mental distress in Australia. The common causes of chronic stress include things such as being in debt, having a low income, poor working conditions, or being exposed to racism or domestic violence. "Governments evade the problem by persisting with individualised, medicalised, drug-based strategies," he says. "These strategies aren't reducing high rates of mental distress, sometimes do harm, and marginalise attention on social causes."

Note: The UK's medicines regulator is launching a review of over 30 commonly prescribed antidepressants, including Prozac, amid rising concerns about links to suicide, self-harm, and long-term side effects like persistent sexual dysfunction–especially in children. Our latest Substack, Lonely World, Failing Systems: Inspiring Stories Reveal What Sustains Us, dives into the loneliness crisis exacerbated by the digital world and polarizing media narratives, along with inspiring solutions and remedies that remind us of the true democratic values that bring us all together.

The pharmaceutical industry, as a whole and by its nature, is conflicted and significantly driven by the mighty dollar, rather than altruism. A 2020 peer-reviewed article published in the Journal of the American Medical Association outlines the extent of the problem. The group studied both the type of illegal activity and financial penalties imposed on pharma companies between the years 2003 and 2016. Of the companies studied, 85 percent (22 of 26) had received financial penalties for illegal activities with a total combined dollar value of $33 billion. The illegal activities included manufacturing and distributing adulterated drugs, misleading marketing, failure to disclose negative information about a product (i.e. significant side effects including death), bribery to foreign officials, fraudulently delaying market entry of competitors, pricing and financial violations, and kickbacks. The highest penalties were awarded to Schering-Plough, GlaxoSmithKline (GSK), Allergan, and Wyeth. The biggest overall fines have been paid by GSK (almost $10 billion), Pfizer ($2.9 billion), Johnson & Johnson ($2.6 billion), and other familiar names including AstraZeneca, Novartis, Merck, Eli Lilly, Schering-Plough, Sanofi Aventis, and Wyeth. Five US states – Texas, Kansas, Mississippi, Louisiana, and Utah – are taking Pfizer to court for withholding information, and misleading and deceiving the public through statements made in marketing its Covid-19 injection.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

A Supreme Court ruling against the opioid company Purdue Pharma ... substantially raised the bar for executives and owners trying to shield their wealth. Johnson & Johnson, Boy Scouts of America and Rite Aid are among the entities trying to handle a vast number of lawsuits in bankruptcy court, seeking to resolve all claims in a single settlement. These proceedings have echoes of the Purdue Pharma case decided by the Supreme Court on Thursday, in which the Sackler family, which owns the bankrupt opioid-maker, offered plaintiffs about $6 billion of the $11 billion they extracted from the company. In exchange, family members would have received immunity from future lawsuits, without filing for bankruptcy themselves. A 5-4 Supreme Court held that settlement was inadequate. Its ruling threw the massive bankruptcy case against Purdue Pharma into doubt after years of court battles over the company's role in the nation's opioid epidemic. The decision also adds a fresh wrinkle to a controversial legal strategy, called the Texas two-step, in which companies use a Texas law to split into separate companies and shift a large volume of legal claims onto the newly created entity. In the second step, the entity carrying the lawsuits files for bankruptcy and seeks to release its parent organization from all liability in exchange for a payout. Johnson & Johnson transferred some of its assets and all of the legal claims against it over asbestos-tainted talcum powder into a new legal entity that filed for Chapter 11. Boy Scouts of America ... agreed to pay $2.5 billion to settle claims of sexual abuse in bankruptcy court, a deal that shields from future litigation insurance companies as well as schools, churches and community organizations involved with the nonprofit.

Note: For more like this, read about how powerful corporations use the bankruptcy system to dodge lawsuits over sexual abuse and deadly products. Along US opioid industry lines, read how the industry operated like a drug cartel. Watch our Mindful News Brief video on how the deadly War on Drugs protects the activities of the rich and powerful: military-intelligence interests within the US government, big banks, Big Pharma, and drug cartels.

Americans are paying too much for prescription drugs. Pharmacy benefit managers ... are driving up drug costs for millions of people, employers and the government. The three largest pharmacy benefit managers, or P.B.M.s, act as middlemen overseeing prescriptions for more than 200 million Americans. They are owned by huge health care conglomerates – CVS Health, Cigna and UnitedHealth Group – and are hired by employers and governments. The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees. Most Americans get their health insurance through a government program like Medicare or through an employer, which pay for two different types of insurance for each person. One type covers visits to doctors and hospitals, and it is handled by an insurance company. The other pays for prescriptions. That is overseen by a P.B.M. The P.B.M. negotiates with drug companies, pays pharmacies and helps decide which drugs patients can get at what price. In theory, everyone saves money. But those savings appear to be largely a mirage, a product of a system where prices have been artificially inflated so that major P.B.M.s and drug companies can boost their profits while taking credit for reducing prices.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Poison control centers across the US say they are seeing a steep increase in calls related to semaglutide, an injected medication used for diabetes and weight loss, with some people reporting symptoms related to accidental overdoses. Some have even needed to be hospitalized for severe nausea, vomiting and stomach pain, but their cases seem to have resolved after they were given intravenous fluids and medications to control nausea. From January through November, the America's Poison Centers reports nearly 3,000 calls involving semaglutide, an increase of more than 15-fold since 2019. In 94% of calls, this medication was the only substance reported. In most of the calls, people reported dosing errors, said Dr. Kait Brown, clinical managing director of the association. "Oftentimes, it's a person who maybe accidentally took a double dose or took the wrong dose," Brown said. Semaglutide was approved by the US Food and Drug Administration in 2017. It is sold as Ozempic when used for diabetes and Wegovy when used for weight loss. Even when used as directed by a doctor, people can have stomach and bowel side effects, including nausea, vomiting and constipation, especially when they start the drugs. After celebrities began openly embracing Ozempic on social media in 2022 as a way to lose weight, demand overwhelmed supply. There's no specific antidote for a semaglutide overdose.

Note: The money behind the makers of weight-loss drugs is staggering, with the economic value of Wegovy's Novo Nordisk soaring to over $420 billionexceeding the entire GDP of Denmark, its home country. Read more on the significant adverse effects associated with these drugs. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Nicholas England, a healthy 22-year-old from Virginia, shot himself in the head in 2017, less than two weeks after he started taking an allergy medicine that had been linked for years to episodes of depression and suicidal thinking. His parents soon started exploring a lawsuit against Merck, the developer of the blockbuster asthma and allergy drug, Singulair. Nicholas had no history of mental-health problems, they said. The Englands were shocked to learn from legal advisers that they had no case. Like countless other potential plaintiffs, they had run into one of Corporate America's most effective liability shields: the legal doctrine of preemption, the principle that federal law supersedes state law. Armed with U.S. Supreme Court rulings on preemption starting in the 1990s, companies increasingly argue that federally regulated products or services should be immune from lawsuits alleging state-law violations. State laws historically have provided the legal basis for some of the most common lawsuits against U.S. companies alleging injuries, deaths or illnesses caused by negligence or defective products. Pending lawsuits against Merck allege that the company's own early research indicated the drug could impact the brain but that Merck downplayed any risks in statements to regulators. It wasn't until 2020 that the FDA slapped its most serious warning, called a "black box," on the drug's label. By that time, the FDA had received more than 80 reports of suicides in people taking the medicine.

Note: Read more about Singulair and its dangers to human health, along with the tremendous financial conflicts of interests resulting in the FDA protecting the pharmaceutical industry first, and the health of the people second. For more along these lines, see concise summaries of deeply revealing news articles on pharmaceutical industry corruption from reliable major media sources.

This year, Pfizer expects to bring in $36 billion from worldwide sales of its COVID-19 vaccine. That would shatter the previous record in annual sales for a single pharmaceutical product - about $20 billion for the anti-inflammatory drug Humira - and make the Pfizer vaccine the bestselling pharmaceutical product ever. Moderna will deliver fewer doses but is still expecting up to $18 billion in sales for the year for its COVID-19 vaccine. Humira, has been ... churning out tens of billions of dollars a year for multiple years on end. And it's not entirely clear that the mRNA vaccines will do that. Just because Pfizer and Moderna are selling billions of doses now doesn't mean that will last forever. The vaccines could work so well they eliminate the need for further boosters, though it's also possible COVID shots could become routine, like flu shots. The uncertainty puts a premium on maximizing sales now. Any vaccine manufacturer is going to realize that there's a risk that they're going to have a very short lifecycle. Moderna got a lot of government funding, offsetting costs and minimizing risks. But the COVID-19 vaccine is its only product on the market. Pfizer, on the other hand, didn't accept early government investment and took on a lot of those upfront costs itself. But it has dozens of other products in its portfolio that it makes and will continue to make once the pandemic ends.

Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines and Big Pharma profiteering from reliable major media sources.

Jada Renee Louis of Newport News, Virginia, died on 22 June 2019 about a week after requiring emergency hospital care for diabetic ketoacidosis, a serious complication caused by a lack of insulin, and a foot ulcer. She was 24. A type 1 diabetic, Louis, who did not have health insurance coverage, couldn’t afford the cost of her insulin doses and pay her rent. She chose to skip doses in order to pay her rent. Today a vial of insulin – which will last 28 days once opened – costs about $300 in the US. “People are literally dying over $300 like my sister did. People shouldn’t have to choose between medications or shelter. That’s the most outrageous decision for somebody to have to make, yet people are doing it daily,” Jazmine Baldwin, Louis’s sister, [said]. Price gouging of insulin and other barriers to accessing it are symptomatic of America’s broken healthcare system, diabetes advocates argue, and the resulting deaths and struggles of those with diabetes demonstrate the need for systemic reforms. Between 2012 to 2016, the average cost of insulin in the United States nearly doubled to $5,705 per year for individuals with type 1 diabetes. Production costs for a vial of insulin are estimated to cost around $5 while pharmaceutical companies charge as high as $540 per vial and Americans are dying as a result of being unable to afford it in addition to the expensive costs of medical care, and supplies such as syringes and glucose monitors. Some 1.25 million Americans are currently diagnosed with type 1 diabetes.

Note: For more along these lines, see concise summaries of deeply revealing news articles on pharmaceutical industry corruption from reliable major media sources.

Joan Doyle trusts her doctors. Between her husband's epilepsy and diabetes, her daughter's Down syndrome and her own car accident years ago, the 65-year-old Sharonville resident and her family have relied on a whole host of doctors to guide them through new diagnoses and prescriptions. So when she searched her family's doctors in Open Payments, a public database that shows which doctors have received money from Big Pharma, Doyle was curious about what she'd find. "Certainly none of my doctors are on this list," she remembered thinking before searching the database. She was surprised. "Every single one of them," Doyle said. "Everybody from our dentist to our family doctor to all of our ologists." All 12 of the doctors Doyle searched accepted payments or in-kind forms of compensation from pharma or medical device companies between 2017 and 2023. The total sum varied widely, from less than $300 for her OB-GYN to more than $150,000 for her husband's oncologist. Payments like these are pervasive: A 2024 analysis found that more than half of doctors in the U.S. accepted a payment from a pharmaceutical or medical device company over the past decade. Most don't earn millions of dollars ... but research shows that when a doctor was bought a single meal of less than $20 by a drug company, they were up to twice as likely to prescribe the medication the company was marketing.

Note: 60% of U.S. doctors who shaped the DSM-5-TR–the "bible" of psychiatric diagnosis–received $14.2 million from the drug industry, raising concerns over conflicts of interest in psychiatric guidelines. For more along these lines, read our concise summaries of news articles on health and Big Pharma profiteering.

The pharma firms behind blockbuster weight loss drugs could face up to 10,000 lawsuits from patients who claim the drugs caused debilitating side effects like stomach paralysis and 'tearing holes' in the food pipe. Ozempic and sister shots like Wegovy and Mounjaro have recently come under fire over claims that the injections cause a roster of complications patients were allegedly not warned about. One woman told DailyMail.com that she suffered life-threatening stomach paralysis after taking Mounjaro, and has now joined a massive lawsuit against its maker Eli Lilly and Ozempic manufacturer Novo Nordisk. She claims she may never eat a solid meal again. Another said Ozempic caused so much internal damage she had to have her gallbladder removed, while another said the drug induced such violent vomiting it tore a hole in her esophagus. Now, Robert Peirce & Associates, a law firm based in Pittsburgh, estimates that the number of plaintiffs could explode to as many as 10,000. In addition to lawsuits, some patients have also claimed the drugs caused suicidal thoughts, psychosis, and appearance issues like deflated breasts. 'Unfortunately, the manufacturers of Ozempic and other GLP-1 agonists failed to adequately warn of the associated risks,' the Robert Peirce & Associates team wrote. Attorney Ken Moll ... said it was 'unconscionable' that the firms still hadn't added warnings to their labels which warn about the risk of gastroparesis and stomach paralysis.

Note: It is now estimated that 1 in 8 adults in the US have taken Ozempic or another weight-loss drug. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Louis Milione retired from the DEA a second time this summer amid reporting by The Associated Press on potential conflicts caused by his prior consulting for the pharmaceutical industry. Less than three months later, Milione again landed a plum job at Guidepost Solutions, a New York-based firm hired by some of the same companies he had been tasked with regulating when he returned to the DEA in 2021. Milione had spent four years at Guidepost prior to his return, leveraging his extensive experience and contacts from a 21-year DEA career. Milione is the most senior of a slew of DEA officials to have traded their badge and gun for a globe-trotting consulting job. His career stands out for two cycles through the revolving door between government and industry, raising questions about the potential impact on the DEA's mission to police drug companies blamed for tens of thousands of American overdose deaths. Milione's private-sector clientele also included Morris & Dickson Co., the nation's fourth-largest wholesale drug distributor, as it tried to stave off DEA sanctions for disregarding thousands of suspicious, high-volume orders. The DEA allowed the company to continue shipping drugs for nearly four years after a judge recommended its license be revoked for "cavalier disregard" of rules aimed at preventing opioid abuse. It was not until AP began asking questions this spring that the DEA moved to finally strip the Shreveport, Louisiana-based company of its license to distribute highly addictive painkillers.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry from reliable major media sources.

The Centers for Disease Control and Prevention (CDC) has been accused of bowing to drug industry pressure after releasing new guidelines that doctors say put lives at risk by rowing back on warnings about the dangers of opioid prescribing. The latest CDC guidelines have caused controversy after dropping specific limits on dosages and lengths of prescribing from a key summary of recommendations used by physicians. Dr Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing, sees the drug industry's hand behind the change. Kolodny has testified against opioid makers in legal actions over their part in driving the opioid epidemic by pushing sales with false claims about their safety and effectiveness. They include Purdue Pharma, manufacturer of OxyContin, a powerful narcotic pill that kickstarted the US's opioid epidemic alongside the company's marketing strategy to see the drugs widely prescribed. Kolody said ... that the drug industry calculated how much the 2016 CDC guidelines would cost it if doctors followed the recommendations to limit prescribing of high dosage pills. "The highest dosage products have had the highest profit margin. It only costs a few extra pennies to make the higher dosage pill, but retail it's almost double what they get per pill or prescription. So the industry fought very hard to block the release of the 2016 guideline and when that failed they did everything they could to make the guidelines appear controversial. And that worked," he said.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in Big Pharma from reliable major media sources.

Big Pharma spent more than any other industry to lobby Congress and federal agencies this year, a Reuters analysis shows, but is still on course for a major defeat by failing to stop a bill that allows the government to negotiate prices on select drugs. The $430 billion Inflation Reduction Act to change climate, health, and tax policies cleared its largest hurdle last week when Democratic lawmakers passed it in the Senate. The U.S. House of Representatives is also expected to pass it on Friday, allowing President Joe Biden to sign it into law. A Kaiser Family Foundation poll in October found that 83% of Americans, including 95% of Democrats and 71% of Republicans, want the federal Medicare health plan for seniors to negotiate prices. The industry's powerful trade association, Pharmaceutical Research and Manufacturers of America (PhRMA), urged senators in a public letter to reject the bill. A Reuters analysis ... shows that the pharmaceutical industry has spent at least $142.6 million on lobbying Congress and federal agencies in the first half of 2022, more than any industry, and at least $16.1 million on campaign contributions during the current mid-term election cycle. Almost two thirds of the money spent on lobbying ... came from PhRMA and its member companies. The bill's provision for drug price negotiations was scaled back in November, allowing Medicare to focus on an annual maximum of 20 of the costliest medicines by 2029, instead of an initial proposal to help reduce prices for 250 treatments.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry from reliable major media sources.

Covid-19 vaccines have created at least nine new billionaires after shares in companies producing the shots soared. Topping the list of new billionaires are Moderna CEO StÄ‚©phane Bancel and Ugur Sahin, the CEO of BioNTech, which has produced a vaccine with Pfizer. Both CEOs are now worth around $4 billion, according to an analysis by the People's Vaccine Alliance, a campaign group that includes Oxfam, UNAIDS, Global Justice Now and Amnesty International. Senior executives from China's CanSino Biologics and early investors in Moderna have also become billionaires on paper as shares skyrocketed. Moderna's share price has gained more than 700% since February 2020, while BioNTech has surged 600%. CanSino Biologics' stock is up about 440% over the same period. The company's single-dose Covid-19 vaccine was approved for use in China in February. Activists said the wealth generation highlighted the stark inequality that has resulted from the pandemic. The nine new billionaires are worth a combined $19.3 billion, enough to fully vaccinate some 780 million people in low-income countries. "These billionaires are the human face of the huge profits many pharmaceutical corporations are making from the monopoly they hold on these vaccines," Anne Marriott, Oxfam's health policy manager, said. "These vaccines were funded by public money and should be first and foremost a global public good, not a private profit opportunity," she added.

Note: You would hope that with all the suffering going on in our world, big Pharma wouldn't gouge and make huge profits on their vaccines. Sadly, this is far from the truth. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and the coronavirus vaccine from reliable major media sources.

The pharmaceutical industry is pouring resources into the growing political fight over generic coronavirus vaccines. Over 100 lobbyists have been mobilized to contact lawmakers and members of the Biden administration, urging them to oppose a proposed temporary waiver on intellectual property rights by the World Trade Organization that would allow generic vaccines to be produced globally. Pharmaceutical lobbyists working against the proposal include Mike McKay, a key fundraiser for House Democrats, now working on retainer for Pfizer, as well as several former staff members to the U.S. Office of Trade Representative, which oversees negotiations with the WTO. Several trade groups funded by pharmaceutical firms have also focused closely on defeating the generic proposal, new disclosures show. The U.S. Chamber of Commerce, the Business Roundtable, and the International Intellectual Property Alliance, which all receive drug company money, have dispatched dozens of lobbyists to oppose the initiative. The push has been followed by a number of influential voices taking the side of the drug lobby. Last week, Sen. Thom Tillis, R-N.C., released a letter demanding that the administration "oppose any and all efforts aimed at waiving intellectual property rights." Currently, only 1 percent of coronavirus vaccines are going to low-income countries, and projections show much of the world's population may not be vaccinated until 2023 or 2024.

Note: Has it ever been more clear that big Pharma places profits above health, even when it might cause huge numbers of people to die? For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and coronavirus vaccines from reliable major media sources.

The chairman and CEO of Pfizer, Albert Bourla, sold $5.6 million worth of stock in the pharmaceutical company on Monday. The sale took place on the same day Pfizer announced that its experimental coronavirus vaccine candidate was found to be more than 90% effective. Bourla's sale of Pfizer stock was part of a trading plan set months in advance. Known as 10b5-1 plans, they essentially put stock trades on autopilot. Executives are supposed to adopt these plans only when they are not in possession of inside information that can affect a company's stock price. On Aug. 19, Bourla implemented his stock-trading plan. The next day, Aug. 20, Pfizer issued a press release ... confirming that Pfizer and its German partner, BioNTech, were "on track to seek regulatory review" for its vaccine candidate. Daniel Taylor, an expert in insider trading ... told NPR that the close timing between the adoption of Bourla's stock plan and the press release looked "very suspicious." "It's wholly inappropriate for executives at pharmaceutical companies to be implementing or modifying 10b5-1 plans the business day before they announce data or results from drug trials," Taylor said. The stock sales by Pfizer's CEO brought to mind similar concerns with another coronavirus vaccine-maker, Moderna. Multiple executives at Moderna adopted or modified their stock-trading plans just before key announcements about the company's vaccine. Those executives have sold tens of millions of dollars in Moderna stock.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma profiteering from reliable major media sources.

Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs. Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million. The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May. At that point, the company's share price jumped and official disclosures showed executives cashing in their shares for millions of dollars. Advocates have questioned whether it's appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company's vaccine development. Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules - known as 10b5-1 plans - can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company's vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.

Note: Explore a revealing NBC article titled "Secret, powerful panels will pick Covid-19 vaccine winners." For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma corruption from reliable major media sources.

Moderna CEO StÄ‚©phane Bancel more than tripled the number of his company shares to be sold through an executive stock plan that was changed just days after the biotech in May announced positive early results for its coronavirus vaccine. Moderna's shares spiked on the May news, rising 30% in just one day. After seeking the executive stock plan change in May, Bancel sold more than 72,000 Moderna shares in the first 16 days of July, generating nearly $4.8 million for the executive. That was more than triple the 22,000 shares he had previously scheduled to sell during the same period through the company's executive trading plan. Another top Moderna executive, President Stephen Hoge, also had his pre-programmed executive trading plan reset around the same time. The change allowed him to sell $1.9 million worth of Moderna stock in the first two weeks of July. The executives' ... sales were made through what are known as 10b5-1 stock plans. These arrangements must be set up or amended at least 30 days before any transactions are executed; they are commonly used at publicly traded companies to help shield executives from potential claims of insider trading. The fact that the plans were changed during the pandemic as news was emerging about the company's closely watched coronavirus vaccine raises new questions about how Moderna executives have pocketed millions of dollars in recent months.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma profiteering from reliable major media sources.

The origin, evolution and astonishing scale of America’s catastrophic opioid epidemic just got a lot clearer. The drug industry - the pill manufacturers, wholesalers and retailers - found it profitable to flood some of the most vulnerable communities in America with billions of painkillers. They continued to move their product, and the medical community and government agencies failed to take effective action, even when it became apparent that these pills were fueling addiction and overdoses and were getting diverted to the streets. This has been broadly known for years, but this past week, the more precise details became public for the first time. The revelatory data comes from the Drug Enforcement Administration and its Automation of Reports and Consolidated Orders System (ARCOS). “This really shows a relationship between the manufacturers and the distributors: They were all in it together,” said Jim Geldhof, a retired DEA employee. “We’re seeing a lot of internal stuff that basically confirms ... that it was all about greed, and all about money.” The data shows a trend in pill distribution that, according to the lawsuit plaintiffs, can’t be passed off as reasonable therapeutic medical treatment. The industry shipped 76 billion oxycodone and hydrocodone pills across the country from 2006 through 2012, the period covered by the ARCOS data released this past week. These pills didn’t flow in a steady stream but were more like a flash flood, spiking from 8.4 billion in 2006 to 12.6 billion in 2012.

Note: For more along these lines, see concise summaries of deeply revealing news articles on pharmaceutical industry corruption from reliable major media sources.

A team of researchers inside Pfizer made a startling find in 2015: The company’s blockbuster rheumatoid arthritis therapy Enbrel, a powerful anti-inflammatory drug, appeared to reduce the risk of Alzheimer’s disease by 64 percent. The results were from an analysis of hundreds of thousands of insurance claims. Verifying that the drug would actually have that effect in people would require a costly clinical trial - and after several years of internal discussion, Pfizer opted against further investigation and chose not to make the data public, the company confirmed. Researchers in the company’s division of inflammation and immunology urged Pfizer to conduct a clinical trial on thousands of patients, which they estimated would cost $80 million ... according to an internal company document obtained by The Washington Post. Pfizer’s deliberations, which previously have not been disclosed, offer a rare window into the frustrating search for Alzheimer’s treatments inside one of the world’s largest drug companies. Pfizer did share the data privately with at least one prominent scientist, but outside researchers contacted by The Post believe Pfizer also should at least have published its data, making the findings broadly available to researchers. “Of course they should. Why not?” said Rudolph E. Tanzi, a leading Alzheimer’s researcher and professor at Harvard Medical School. “It would benefit the scientific community to have that data out there,” said Keenan Walker, an assistant professor of medicine at Johns Hopkins.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.